Business
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\nBriefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform Monetization Strategy\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (Nasdaq: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced it will host an investor, analyst and shareholder briefing on Thursday, April 9, 2026 at 8:30 AM Eastern featuring a live demonstration of withZeta.ai — the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design. The briefing will be conducted via live webcast and will cover the platform’s capabilities and commercial architecture, the rare cancer market opportunity, competitive positioning, and the Company’s near-term revenue strategy and growth roadmap. Registration is available at: Zoom link https://us06web.zoom.us/webinar/register/1017749924357/WN_o7JaBBCxRDSfEzN6eUCwQA.\n\n\nThe withZeta.ai Briefing\n\n\nThe investor and analyst briefing will be hosted by Panna Sharma, President and Chief Executive Officer and Kishor Bhatia, Ph.D., FRCP, Chief Scientific Officer of Lantern Pharma, and will cover the following:\n\n\n1. The rare cancer imperative — why millions of patients across hundreds of distinct cancer types remain systemically underserved and why AI co-scientists are part of the solution\n2. Live demonstration of withZeta.ai — the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design\n3. Platform capabilities and what makes withZeta.ai fundamentally different and an economic imperative in drug discovery and development.\n4. Commercial subscription model, revenue strategy, and market opportunity\n5. Competitive position in the AI drug discovery landscape\n6. Strategic roadmap and upcoming milestones for withZeta.ai\n\n\n“withZeta.ai is built on a foundation that took years of our team’s work to ideate and assemble — 12 FDA designations across orphan, pediatric rare disease, and fast track classifications for Lantern, and several more earned by our collaborators. We have three drugs in precision oncology clinical trials with over 100 patients successfully dosed and studied. That heritage of clinical and regulatory recognit...